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A Hypermorphic Missense Mutation in PLCG2,
Encoding Phospholipase Cg2, Causes a Dominantly Inherited
Autoinflammatory Disease with Immunodeficiency
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Debra A. Long Priel,6 Amanda Ombrello,1 Deborah Stone,1 Michael J. Ombrello,1 Javed Khan,7
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Whole-exome sequencing was performed in a family affected by dominantly inherited inflammatory disease characterized by recurrent
blistering skin lesions, bronchiolitis, arthralgia, ocular inflammation, enterocolitis, absence of autoantibodies, and mild immunodefi-
ciency. Exome data from three samples, including the affected father and daughter and unaffectedmother, were filtered for the exclusion
of reported variants, along with benign variants, as determined by PolyPhen-2. A total of eight transcripts were identified as possible
candidate genes. We confirmed a variant, c.2120C>A (p.Ser707Tyr), within PLCG2 as the only de novo variant that was present in
two affected family members and not present in four unaffected members. PLCG2 encodes phospholipase Cg2 (PLCg2), an enzyme
with a critical regulatory role in various immune and inflammatory pathways. The p.Ser707Tyr substitution is located in an autoinhi-
bitory SH2 domain that is crucial for PLCg2 activation. Overexpression of the altered p.Ser707Tyr protein and ex vivo experiments using
affected individuals’ leukocytes showed clearly enhanced PLCg2 activity, suggesting increased intracellular signaling in the PLCg2-medi-
ated pathway. Recently, our laboratory identified in individuals with cold-induced urticaria and immune dysregulation PLCG2 exon-
skipping mutations resulting in protein products with constitutive phospholipase activity but with reduced intracellular signaling at
physiological temperatures. In contrast, the p.Ser707Tyr substitution in PLCg2 causes a distinct inflammatory phenotype that is not
provoked by cold temperatures and that has different end-organ involvement and increased intracellular signaling at physiological
temperatures. Our results highlight the utility of exome-sequencing technology in finding causal mutations in nuclear families with
dominantly inherited traits otherwise intractable by linkage analysis.Autoinflammatory diseases are inherited immunologic
disorders caused by aberrant activation of innate immune
cells, primarily neutrophils and macrophages. In a broad
sense, autoinflammatory diseases could be defined as pri-
mary immunodeficiencies because they result from defects
in components of the innate immune response. The term
autoinflammationwas coinedwith the intent of distinguish-
ing this category of illnesses from the more commonly
recognized autoimmune inflammatory diseases that are
largely mediated by effectors of the adaptive immune
system, namely autoreactive T cells and autoantibodies.
Autoinflammatory syndromes include both monogenic
and polygenic diseases that manifest as life-long recurrent
episodes of systemic inflammation and are accompanied
by organ-specific involvement typically affecting the
serosa, skin, joints, bones, gastrointestinal tract, and occa-
sionally the CNS. Genome-wide linkage analysis, posi-
tional cloning, and candidate-gene screening have led to
the identification of mutations in 12 genes associated
with various monogenic autoinflammatory diseases.1
Discovering the genetic causes of autoinflammatory
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The Americmunobiology and particularly the importance of pathways
regulating the cytokine IL-1b. Without advanced tech-
niques in genetic analysis, many of these disorders might
have gone unrecognized as members of a phenotypically
diverse group. However, the identification of causative
mutations in autoinflammatory diseases is limited by their
rarity within the general population and the lack of large
multicase families. A significant number of genetically un-
characterized affected subjects are sporadic cases or come
from small families underpowered for linkage analysis.
Recent advances in high-throughput sequencing technol-
ogies have allowed a search for causal variants in families
that are affected by recessively inherited diseases and
that have as few as one or two affected individuals. Never-
theless, small families affected by dominantly inherited
and sporadic phenotypes remain a challenge for analysis.
The individuals described here include affected father
II-1 and daughter III-2 (Figures 1 and 2), who both suffer
from early-onset recurrent blistering skin lesions, nonspe-
cific interstitial pneumonitis with respiratory bronchiolitis
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Figure 1. Clinical Manifestations in Two
Individuals with the p.Ser707Tyr Substitu-
tion in PLCg2
The inflammatory skin lesions observed in
these affected individuals include recur-
rent eruptions of erythematous plaques
(A) and vesiculopustular lesions (B) and
the frequent evolution of skin lesions
into cellulitis (C).
(D) A dense interstitial and perivascular
inflammatory infiltrate in the dermis is
composed of lymphocytes, histiocytes,
eosinophils, and much karyorrhectic
nuclear debris. Karyorrhectic nuclear
debris is typically seen in neutrophilic
dermatosis.sinopulmonary infections and by a paucity of circulating
antibodies (IgM and IgA). Both individuals tested nega-
tive for autoantibodies on multiple occasions. Both indi-
viduals developed a full-body epidermolysis-bullosa-like
eruption in infancy, but this later evolved to recurrent
erythmatous plaques and vesiculopustular lesions that
worsen with heat and sun exposure (Figures 1A–1C).
Biopsy of open skin lesions revealed a dense infiltrate
of neutrophils, eosinophils, histiocytes, and lymphocytes
(Figure 1D). At the age of 6 months, individual III-2 devel-
oped recurrent abdominal pain with bloody diarrhea and
was colonoscopically diagnosed with ulcerative colitis at
the age of 2 years. Eye involvement became evident at
the age of 8 months when small blisters were discovered
around her cornea; these blisters ultimately progressed
into corneal erosions, ulcerations, intraocular hyperten-
sion, and more recently, cataracts. Her father (II-1) suffered
similar dermatological lesions sensitive to the same
stimuli, in addition to a history of recurrent sinopulmo-
nary infections. At the age of 18 years, he was diagnosed
with ‘‘lazy leukocyte syndrome’’ (impaired leukocyte che-
motaxis [MIM 150550]).
More recent lymphocyte phenotyping revealed a
near complete absence of class-switched memory B cells
(CD20þ CD27þ IgM- IgAþ or IgGþ), potentially explain-
ing the increased propensity for developing bacterial infec-
tions. The distribution and number of circulating naive
and memory T cells were normal, as were those of NK cells;
however, NK Tcell numbers were lower in both individuals
(Table S1, available online). Intracellular IFN-g and IL-17
production of mitogen-activated T cells was similar to
that of controls (data not shown), as was IFN-g production
in response to an array of TLR agonists; the only exception714 The American Journal of Human Genetics 91, 713–720, October 5, 2012was a diminished response to a TLR8
agonist, ssRNA40 (Figures 3A and
3B). Both individuals were refractory
to treatment with nonsteroidal anti-
inflammatory drugs and TNF in-
hibitors, and they were partially
responsive to an IL-1 inhibitor. Their
inflammatory manifestations wereameliorated by high-dose corticosteroids, but the dosage
and duration of treatment have been limited by side
effects. The paternal grandparents, mother, and brother
of individual III-2 were unaffected, and DNA samples
from all family members were available for analysis. All
individuals (or parents of minors) provided written in-
formed consent as approved by the institutional review
board at the National Institute of Arthritis and Musculo-
skeletal and Skin Diseases and National Institute of Dia-
betes and Digestive and Kidney Diseases.
To identify the causativemutation in this family affected
by uncharacterized systemic inflammatory disease and
without similar cases reported in the literature, we se-
quenced the exomes of the affected father (II-1) and
daughter (III-2) and the unaffected mother (II-2). Targeted
exon enrichment was performed on 3 mg of DNA extracted
from peripheral blood with the use of the SureSelect
Human All Exon 50 Mb Kit (~24,000 genes, Agilent Tech-
nologies). The exon-enriched DNA libraries were subjected
to paired-end sequencing with the SOLiD 4.0 System plat-
form (Applied Biosystems). Sequence data were mapped
with SOLiD Bioscope software version 1.2 and hg18
human genome as a reference. Reads withmapping quality
below 10 and potential duplicates were removed. We
achieved an average of 15 Gb of mappable sequences
with a mean coverage of 803; 80% of targeted bases were
covered sufficiently for variant calling (>103 coverage).
Single-nucleotide substitutions and small indels were iden-
tified with SAMtools 0.1.11,2 bam2mpg,3 and Dindel.4
Calls with a read coverage less than 103 and a Phred-scaled
variant quality less than 20 were filtered out.
For individuals III-2, II-1, and II-2, there remained
51,744, 50,855, and 47,023 SNPs, respectively, and 3,514,
Figure 2. Exome Sequencing Identifies a DeNovo PLCG2 c.2120C>AMutation in a Family Affected by Systemic Inflammatory Disease
(A) Schematic representation of the exome-data-filtering approach under the assumption of dominant inheritance in the family. The
following abbreviations are used: MS, missense variant; SS, splice-site variant; stop, stop-codon variant; FS, frameshift indel; and NFS,
nonframeshift indel.
(B) A pedigree of the family shows the unaffected grandparents and the affected father and daughter and indicates that the disease-caus-
ative mutation (c.2120C>A) arose as a de novo event in the affected father (II-1) and was dominantly inherited in the third generation.
Sanger sequencing confirmed complete cosegregation of p.Ser707Tyr in PLCg2 within the family.
(C) The evolutionary conservation of the p.Ser707Tyr substitution of PLCg2. Sequence alignment of PLCg2 among various species
shows that Ser707 (red indicated with an arrow) is a highly conserved residue.
(D) Structure of C-terminal SH2 (cSH2) and SH3 domains of PLCg2. The top panel shows a schematic representation of PLCg2 and the
location of the p.Ser707Tyr substitution. The p.Ser707Tyr substitution is not located within the catalytic domain of PLCg2 (X-box ¼
316–458; Y-box ¼ 926–1,029) but is located in the cSH2 domain. The lower panel shows a three-dimensional structural model of the
PLCg2 cSH2 domain (green) and SH3 domain (orange) with the use of homology modeling by SWISS-Model. The substitution of
Ser707 (blue) with Tyr (red) lies in the cSH2 domain. The three known phosphorylation sites are depicted in magenta; Tyr733 is located
in the cSH2 domain, whereas Tyr753 and Tyr759 are located in the linker region (blue gray) between the cSH2 domain and the SH3
domain.2,645, and 3,389 indels, respectively, after quality
screening. SeattleSeq SNP annotation and ANNOVAR
programs5 were then used for categorizing all variants,
of which 6,320 were identified as either missense, splice
site, or nonsense variants and 253 were identified as
coding indels (Figure 2A). Filtering for novel (not available
in any database) variants was performed on the basis
of comparisons to dbSNP132, the 1000 Genomes Pilot
Project (May 2011), the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project (ESP5400),
and 65 additional exomes from internal data. Next, we
applied filtering for dominant inheritance present in the
affected father and daughter, but not in the unaffected
mother, which reduced the number of variants to 32,The Americincluding 29 SNPs and three indels. Five out of the 29
SNPs passed through the conservation analysis on the
basis of the degree of nucleotide-level evolutionary con-
servation (with the use of Genomic Evolutionary Rate
Profiling [GERP])6 and functional-impact prediction on
protein by PolyPhen-2, resulting in a total of eight candi-
date variants (Figure 2A and Table S2).
Sanger sequencing of the eight variants in all family
members (I-1, I-2, II-1, II-2, III-1, and III-2) validated a mis-
sense variant, a C to A change in exon 20 (c.2120C>A;
RefSeq accession number NM_002661.3) of PLCG2
(MIM 600220); this mutation converts Ser707 to Tyr (p.
Ser707Tyr) and is the only de novo mutation in the father
and in complete segregation with the disease status in thisan Journal of Human Genetics 91, 713–720, October 5, 2012 715
Figure 3. IFN-g Production in Stimulated PBMCs and Immunophenotyping of Expanded Individual B Cells
(A and B) Peripheral-blood mononuclear cells (PBMCs) were isolated from heparinized blood and cultured in the presence of the indi-
cated agonists for 48 hr. The harvested supernatant was analyzed for the IFN-g production bymultiplex cytokine analysis. The indicated
control was representative of multiple different healthy controls.
(C) B cell expansion in response to CpG and SAC stimulation of the affected individual, control, and PLAID PBMCs for 4 days is shown
here as the fold increase from baseline after expansion in the percentage of B cells. The percentage of B cells among input or cultured
PBMC was measured by flow cytometry.
(D) IgG- or IgA-positive B cells from the cultures in (C) are measured by ELISPOT in the control, affected individual, and PLAID PBMCs.
They are represented as Ig-positive cells per million B cells in the initial PBMC culture.family (Figure 2B). We evaluated the allele frequency
of mutation c.2120C>A (p.Ser707Tyr) in a panel of 376
Ashkenazi Jewish healthy controls (paternal ancestry)
and 368 control DNA samples of European descent
(maternal ancestry) by using mass spectrometry (the Se-
quenom homogeneous MassExtend assay, Sequenom,
San Diego, CA). With a total of 1,488 genotyped control
chromosomes, we could sufficiently achieve greater than
95% power to detect a normal variant in the popula-
tion with an allele frequency of 1%.7 The c.2120C>A
(p.Ser707Tyr) mutation was not detected in any of the
control DNA samples, suggesting that it is most likely a
disease-causing variant in this family.
PLCG2 encodes phospholipase Cg2 (PLCg2), an enzyme
responsible for ligand-mediated signaling in cells of the
hematopoietic system, and plays a key role in the re-
gulation of immune responses. The lipase activity of
most phospholipases is basally repressed, and the X/Y
linker inserted within the catalytic domain contributes
to this autoinhibition. On the basis of studies of PLCg1,
it has been suggested that the autoinhibition can be
relieved upon phosphorylation of the protein by receptor
tyrosine kinases (RTKs) and subsequent conformational
changes.8 The p.Ser707Tyr substitution in PLCg2 affects
a residue highly conserved throughout vertebrates (Fig-716 The American Journal of Human Genetics 91, 713–720, Octoberure 2C). The evolutionary conservation of p.Ser707Tyr
was measured by the GERP score that was calculated on
34 mammalian species and by the PhastCons score9 based
on 17 vertebrate species. A GERP score > 2 or a PhastCons
score close to 1 is commonly used as an indication of
evolutionary conservation. The GERP and PhastCons
scores for p.Ser707Tyr are significantly high at 4.64 and
0.953, respectively. In addition, the substitution occurs in
the highly conserved C-terminal copy of a tandem pair of
PLCg2 SH2 domains (cSH2), which, along with the nSH2
domain, SH3 domain, and a split PH domain, comprise
the PLCg-specific array, gSA. This regulatory region is
placed within the X/Y linker and contains sites of interac-
tion with regulatory proteins and also elements of auto-
inhibition. The cSH2 domain is crucial for activation of
PLCg2 as a result of its role in repression of the intrinsic
enzyme’s activity because it incorporates the main auto-
inhibitory regions.8 In general, mutations affecting the
SH2 domain in a variety of signaling proteins are directly
involved in ligand binding, affect residues interacting
with the catalytic domain, or cause SH2 domain destabili-
zation.10 Our recent data suggest that Ser707 is located
on the surface of the cSH2 domain that is directly involved
in autoinhibition of the catalytic region of PLCg2 (unpub-
lished data).5, 2012
Figure 4. The p.Ser707Tyr Substitution
Enhances PLCg2 Activity and Intracellular
Ca2þ Flux via the IP3 Signaling Pathway
(A) PLCg2 activity was assayed in COS-7
cells transfected with wild-type (WT)
or p.Ser707Tyr altered PLCg2 constructs.
[3H]inositol phosphate production was
measured after stimulation with 10 ng/ml
epidermal growth factor (EGF). PLCg2
levels were analyzed by immunoblot assay
(insets).
(B) The WT PLCg2 construct (#RC200442,
Origene, Rockville, MD) and the p.Ser707-
Tyr altered PLCg2 construct (Site-Directed
Mutagenesis Kit, QuikChange II, Strata-
gene-Agilent Technologies, Santa Clara,
CA) were transiently introduced into 293T
cells with Lipofectamine 2000 according
to the manufacturers’ protocols. The trans-
fected 293T cells were treated for 1 hr with
EGF (150 ng/ml, #CN02, Cytoskeleton,
Denver, CO) for Rac-mediated PLCg2 acti-
vation and were subjected to the IP-one
assay. The IP1 (surrogate for IP3) level in
the cell lysate was measured by IP-One
ELISA (#72IP1PEA,Cisbio, Bedford,MA) ac-
cording to themanufacturer’s instructions.
(C) Increasing concentrations of PLCg2
WT and p.Ser707Tyr altered constructs
(0, 1.5, or 3.0 mg/106 cells) were transiently
introduced into 293T cells for an assay of
the intracellular Ca2þ level. The transfected 293T cells were plated onto 96-well plates (70,000 cells per well) and treated with EGF
(150 ng/ml) and the calcium-indicating dye (Calcium Assay Kit 640176, BD Biosciences, San Diego, CA). The plates were cooled
down to room temperature for 15 min, and the relative fluorescence was measured every 10 s for the duration of 6 min with the use
of Victor (PerkinElmer, Waltham, MA) according the manufacturers’ manuals.
(D) The protein levels of PLCg2 WT and p.Ser707Tyr altered constructs in 293T cells were confirmed by immunoblot assay.
All graphs represent three or four independent experiments, and error bard indicate the mean5 the standard error of the mean (SEM).p.Ser707Tyr is also in close proximity to the three known
phosphorylation sites, of which Tyr733 is located in the
same cSH2 domain, whereas Tyr753 and Tyr759 are both
located within a linker region next to the cSH2 domain
(Figure 2D), suggesting that the p.Ser707Tyr substitution
might possibly create a new phosphorylation site in
PLCg2. In that case, the extra phosphorylation site might
generate a more easily and efficiently inducible form of
PLCg2. On the basis of computational predictions with
PolyPhen-2 (PSIC score difference ¼ 2.21) and SIFT (toler-
ance index score ¼ 0.02), it is likely that this variant might
affect protein function, although determining the exact
role that the p.Ser707Tyr substitution plays will require
further molecular and structural analyses of PLCg2. Given
this information and the dominant inheritance of the
trait, we predicted that the p.Ser707Tyr substitution might
render an increased function in PLCg2 signaling pathways.
Upon stimulation with various immune receptors,
PLCg2 cleaves the membrane-bound phospholipid phos-
phatidyl inositol-4, 5-biphosphate (PIP2) into the second
messenger molecules inositol-1,4,5-trisphosphate (IP3)
and diacylglycerol (DAG).11 IP3 increases intracellular
calcium levels by inducing the release of endoplasmic
reticulum (ER) calcium stores.12 The released intracellular
Ca2þ then activates protein kinase C (PKC), which subse-
quently activates a number of pathways in the cell. DAGThe Americremains on the cell membrane and potentiates the sig-
naling cascade by activating some PKC enzymes and other
targets. In human T cells, DAG accumulation in the cell
membrane causes RasGRP translocation and activation
through its binding to DAG and thus leads to activation
of the Raf/Mek/Erk pathway.13 Therefore, our working
hypothesis was that if p.Ser707Tyr is a hypermorphic sub-
stitution, we should observe an increase in production of
IP3, along with an increase in intracellular Ca
2þ release
and an increase in phosphorylation of a molecule down-
stream of DAG.
Transient transfection of the mutant p.Ser707Tyr con-
struct in either human embryonic kidney (HEK) 293T cells
or COS7 cells resulted in increased EGF-stimulated pro-
duction of intracellular IP3 and/or IP1, which is a surrogate
measure for IP3 production
14 (Figures 4A and 4B). The
binding of IP3, a product of PLCg2 activity, to IP3 receptors
in themembrane of the ER has been shown to cause a rapid
and transient release of Ca2þ from the ER Ca2þ stores into
the cytosol. Consistent with the observed increased IP3
production, cells transfected with the mutant p.Ser707Tyr
construct exhibited increased intracellular Ca2þ release
after stimulation (Figures 4C and 4D).
To further confirm the causal role of the p.Ser707Tyr
substitution and to address the physiological significance
of results from an overexpression cellular system, wean Journal of Human Genetics 91, 713–720, October 5, 2012 717
Figure 5. Affected Individuals’ PBMCs
Exhibit Significantly Higher PLCg2 Ac-
tivity
PBMCs of two healthy controls—the unaf-
fected mother (II-2) and another healthy
control—and two affected individuals (III-
2 and II-1) were isolated and subjected to
IP-one (A) and intracellular Ca2þ (B) assays.
PBMCs were coated with IgE anti-Dinitro-
phenyl (DNP) mAb (#D8406, 10 mg/ml,
Sigma-Aldrich, St. Louis, MO) for 2 hr
and then stimulated with DNP-albumin
(#A6661, 100 ng/ml, Sigma-Aldrich). The
graphs represent the mean 5 SEM from
three or four independent experiments.
Error bars indicate the SEM.
(C) Affected individuals’ cells show in-
creased ERK phosphorylation. CD19 B
cells from individuals III-2 and II-1, a
healthy control sample, and a PLAID-
affected individual were stimulated by
surface anti-IgM crosslinking and analyzed
for expression of phosphorylated ERK.
Lines indicate phosphostaining in unsti-
mulated cells (red) and anti-IgM stimu-
lated cells (blue). The data are representa-
tive of three independent experiments.measured IP1 production and intracellular Ca
2þ release in
affected individuals’ peripheral-blood mononuclear cells
(PBMCs). Upon crosslinking stimulation with IgE, affected
individuals’ cells produced significantly higher IP1 and
released significantly higher amounts of Ca2þ into the
cytosol than did control cells from an unaffected family
member and another healthy control (Figures 5A and 5B).
PLCg2 is a crucial lipid-metabolizing effector enzyme that
is known to activate IkB kinase (IKK) and extracellular
signal-related kinase (ERK) in CD19 B cells. After stimu-
lating CD19þ cells by crosslinking surface IgM, we ob-
served that the levels of phosphorylated ERK in cells
from both individuals carrying the p.Ser707Tyr substitu-
tion were well above those seen in healthy control samples
(Figure 5C). All together, our data from exogenous expres-
sion and ex vivo experiments demonstrate evidence that
p.Ser707Tyr in PLCg2 is a hypermorphic substitution
that enhances the activity of PLCg2.
Recent work from our laboratory has identified PLCG2
genomic deletions in individuals presenting with a distinct
inflammatory disease manifested by cold-induced urticaria
and immune dysregulation including features of both
immunodeficiency and autoimmunity. We have proposed
the term PLAID (PLCg2-associated antibody deficiency
and immune dysregulation [MIM 614468]) to describe
this disorder.15 The PLAID-associated genomic deletions
disrupt the cSH2 domain of PLCg2, causing failure of auto-
inhibition and resulting in constitutive phospholipase
activity. Interestingly, the gain of constitutive enzymatic
function results in the reduction of distal signaling and
downstream function at physiologic temperatures (Fig-
ure 5C). Ca2þ release in unstimulated B cells from PLAID-
affected individuals increased only upon exposure to low
temperatures, and BCR-stimulated PLAID B cells exhibited718 The American Journal of Human Genetics 91, 713–720, Octoberincreased ERK phosphorylation also with decreasing
temperature. Thus, despite constitutive PLCg2 enzymatic
activity, PLAID-affected individuals have reduced PLCg2-
mediated signal transduction at physiologic temperatures
most likely as a result of a negative feedback caused by con-
stitutive activation. However, PLC signaling is enhanced at
subphysiologic temperatures by a mechanism that under-
pins the pathophysiology of cold-induced skin rash and
inflammation in PLAID-affected individuals.
The p.Ser707Tyr substitution in individuals reported
here compromises autoinhibition, enhances activation,
and exhibits exactly the opposite effects with increased
cellular signaling in mutant cells at physiological tempera-
tures. We speculate that the substitution of Tyr for Ser in
the cSH2 domain might create an extra phosphorylation
site and thus compromises autoinhibition and leads to a
slight increase in basal enzymatic activity that is not suffi-
cient for triggering negative feedback; this therefore causes
enhanced PLCg2 activity upon stimulation with a variety
of upstream signals. Consequently, the individuals with
the p.Ser707Tyr substitution have increased PLCg2-depen-
dent signaling after receptor crosslinking, as indicated by
the elevated levels of IP3 production, intracellular Ca
2þ
release, and ERK phosphorylation.
Of interest, despite the divergent signaling effects seen
in this family’s B cells when compared to PLAID B cells,
both diseases lead to the near absence of circulating
class-switched memory B cells. B cell expansion and
IgGþ B cell accumulation were similar to those of the
controls in stimulated PBMCs. Phenotypic and antibody-
secreting cell frequencies of cultured cells also suggest
a preferential expansion of IgGþ cells compared to IgAþ
B cells; however, in PLAID individuals, all three measures
were impaired (Figures 3C and 3D).15 This implies that5, 2012
the B cell memory defect in these individuals might be
due to a different mechanism from that seen in PLAID.
Potential mechanisms for this phenotype might include
enhanced activation-induced deletion16 (although not
detected in this in vitro assay), in vivo anergy due to
enhanced cellular signaling,17 and enhanced negative
selection of immature B cells.18 Alternatively, the different
mechanism might be a reflection of the relative impact of
exonic deletion versus a missense mutation (c.2120C>A
[p.Ser707Tyr]).
Our finding that p.Ser707Tyr is a gain-of-function substi-
tution in PLCg2 is further corroborated by animal studies
that have implicated the critical role for PLCg2 in regula-
tion of inflammation in mice.19 In the murine phospholi-
pase Cg2 (Plcg2), two missense gain-of-function mutations
introduced by ENU mutagenesis lead to severe sponta-
neous inflammation and autoimmunity. The Ali5 (abnor-
mal limb 5) substitution, p.Asp993Gly, removes a negative
charge from a critical region of the Plcg2 molecule that
ordinarily limits its interaction with the negatively-
charged inner plasma membrane, thereby increasing
enzymatic activity.20 The mice homozygous for the Ali5
substitution suffer from severe inflammation of the
paws, severe skin and eye inflammation, and proliferative
glomerulonephritis. In particular, eye findings include
destruction of the different layers of the corneal epithe-
lium with keratinization, resembling the signs observed
in affected individual III-2. The inflammatory infiltrate in
Ali5 mice is composed of neutrophils, eosinophils, and
lymphocytes, consistent with histopathology findings in
the affected individuals. Similar to our results, the produc-
tion of IP3 is increased in B cells from Ali5 mice and in
WEHI-231 cells expressing mutated Plcg2. Retroviral trans-
fection of altered Ali5 proteins, as compared to wild-type
proteins, induces a stronger Ca2þ flux in primary LPS-
activated wild-type B cells. Ali14, another mouse strain
resulting from ENU mutagenesis, has the p.Tyr495Cys
substitution, which is within the split pleckstrin homology
spPH domain of gSA and enhances activation of Plcg219 by
different signals as a result of compromised autoinhibition.
The Ali14/þ heterozygous mice show an abnormally high
T cell to B cell ratio; upregulation of IgG1, IgG2b, and IgM;
inflammatory arthritis; and metabolic defects.21
In contrast to mice with Ali5 and Ali14 gain-of-function
mutations, Plcg2-deficient mice present with a different
phenotype. Plcg2-null mice exhibit increased perinatal
lethality with gastrointestinal hemorrhages. Although
viable mice can be obtained, they display major functional
defects in B cells, platelets, mast cells, and NK cells and
absent IgM-receptor-induced Ca2þ flux.22 Plcg2-deficient
mice exhibit distinct phenotypes, and some aspects of
these phenotypes are the opposite of those observed in
mice with Plcg2 gain-of function mutations.
Although the precise changes that underlie enhanced
signaling by hypermorphic alterations in PLCg2 remain
to be elucidated, our study offers an important advance
in the field of PLCg2 biology given that PLCG2 disease-The Americassociated missense mutations in humans have not been
described in the past. Furthermore, in concert with the
findings in individuals with PLCG2 deletions, the affected
individuals show the wide phenotypic variability that can
occur with mutations in the same region of the same gene.
The wide phenotypic differences, along with the similari-
ties between the two, namely impaired B cell memory
and immunoglobulin production, suggest that a broad
range of diseases could result from PLCG2 mutations,
and the common theme is involvement of the humoral
immune system and various forms of inflammation.
We propose the term APLAID (autoinflammation and
PLCg2-associated antibody deficiency and immune dysre-
gulation) to distinguish phenotypes caused by missense
PLCG2 mutations from phenotypes caused by genomic
deletions, such as in the case of PLAID-affected individuals.
In conclusion, exome-sequencing technology in a family
with only two affected members identified a mutation in
the PLCG2 pathway as a cause of an autoinflammatory
disease. These results highlight the importance of the
whole-genome approach in elucidating the pathogenesis
of inflammation that would be otherwise missed by a
candidate-gene approach.Supplemental Data
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